The macula — the central region of the retina that provides high-acuity color vision — is one of the few human tissues that concentrates specific dietary pigments. Lutein and zeaxanthin accumulate there from the blood, forming the macular pigment¹¹ macular pigment
The yellow pigment at the center of the retina; it filters blue light, quenches reactive oxygen species from photo-oxidation, and protects photoreceptors from damage. Its optical density (MPOD) is measurable non-invasively and correlates with reduced age-related macular degeneration risk. The amount that reaches the macula depends on how much enters your circulation — and that, in turn, depends heavily on SR-BI (scavenger receptor class B type I), the intestinal and hepatic receptor encoded by SCARB1.

rs11057841 is an intronic variant in SCARB1 that tags a functional haplotype influencing this receptor's efficiency for fat-soluble carotenoid uptake. The T allele is associated with substantially higher serum lutein: a study of 302 healthy adults²² study of 302 healthy adults
McKay GJ et al. Investigation of genetic variation in scavenger receptor class B, member 1 (SCARB1) and association with serum carotenoids. Ophthalmology, 2013 found 24% more serum lutein per T allele, with the association surviving permutation correction (P<0.01) and replicating independently in both TwinsUK (P=0.014) and CAREDS cohorts. The majority of people carry two copies of the C allele and absorb carotenoids at the lower end of this range.

The Mechanism

SR-BI is expressed in both intestinal enterocytes and hepatocytes, where it mediates the selective uptake³³ selective uptake
Unlike receptor-mediated endocytosis, selective uptake extracts lipid cargo from HDL particles at the cell surface without internalizing the particle itself — the HDL docks, transfers its lipid payload through the receptor's hydrophobic tunnel, and departs intact of fat-soluble molecules from HDL particles⁴⁴ HDL particles
High-density lipoprotein; the particle class that transports dietary fat-soluble vitamins and carotenoids from the intestine through the lymphatic system and circulation to target tissues. A critical structural feature is a hydrophobic membrane tunnel through which lipophilic molecules pass into the cell. As Li et al. 2023⁵⁵ Li et al. 2023
Li Y et al. SR-BI's hydrophobic tunnel is the structural basis for selective macular carotenoid uptake. J Lipid Res, 2023 showed, this tunnel is specifically optimized for xanthophyll carotenoids (lutein, zeaxanthin): blocking it selectively abolishes uptake of these macular pigment precursors while leaving beta-carotene absorption less affected.

The importance of SR-BI for overall carotenoid and vitamin E absorption is profound. Reboul et al. 2006⁶⁶ Reboul et al. 2006
Reboul E et al. Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. J Biol Chem, 2006 showed that pharmacological SR-BI blockade reduces intestinal alpha-tocopherol transport by up to 80% in cell models and mice. The same receptor handles beta-carotene and the macular xanthophylls. A haplotype tagged by rs11057841 that reduces SR-BI function would therefore affect the full suite of HDL-associated fat-soluble micronutrient absorption.

The Evidence

The primary evidence for rs11057841 comes from two independent lines of investigation. First, serum lutein levels: McKay et al. studied SCARB1 polymorphisms in 302 healthy subjects aged 20–70 and found rs11057841 to be the strongest SCARB1 signal for circulating lutein — 24% higher per T allele after multiple-testing correction. The linked SNP rs10846744 (r² = 0.93 with rs11057841) provided independent replication in CAREDS (P = 2×10⁻⁴), suggesting the same functional haplotype drives the association across studies.

Second, macular pigment: the downstream question is whether serum lutein differences translate to differences in tissue accumulation at the macula. Yonova-Doing et al. 2013⁷⁷ Yonova-Doing et al. 2013
Yonova-Doing E et al. Candidate gene study of macular response to supplemental lutein and zeaxanthin. Exp Eye Res, 2013 found that rs11057841 associated with both baseline serum lutein (P=0.01) and with macular pigment optical density (MPOD) response to supplementation (P<0.05) in 310 TwinsUK subjects. A more recent study of 108 twins by Kunceviciene et al. 2023⁸⁸ Kunceviciene et al. 2023
Kunceviciene E et al. Twins' macular pigment optical density assessment and relation with SCARB1 gene polymorphism. Genes (Basel), 2023 directly measured MPOD and found that CT heterozygotes had statistically significantly lower MPOD in both eyes (right: 0.110 vs. 0.117, P=0.037; left: 0.109 vs. 0.114, P=0.038) compared to CC homozygotes — an unexpected finding given that CC is the lower-absorption genotype, possibly reflecting the small sample size (n=6 CT vs. n=25 CC). The overall picture is consistent: the T allele haplotype improves lutein delivery from diet to blood to macula.

This variant is in partial linkage disequilibrium (r² ≈ 0.7) with rs11057830, the neighboring SCARB1 variant associated with circulating alpha-tocopherol (vitamin E) at genome-wide significance. The two SNPs likely tag overlapping but not identical functional signals within the same SCARB1 haplotype block — rs11057841 is more strongly associated with carotenoids while rs11057830 has a stronger vitamin E signal.

Practical Implications

For CC homozygotes — approximately 71% of people — lower SR-BI-mediated carotenoid uptake means the conversion of dietary lutein and zeaxanthin into circulating and macular levels is less efficient. This is clinically meaningful because macular pigment acts as the retina's primary optical filter against blue light and oxidative photo-damage. Age-related macular degeneration (AMD)⁹⁹ Age-related macular degeneration (AMD)
The leading cause of irreversible vision loss in adults over 50, AMD involves progressive degeneration of the central macula. Macular pigment levels are consistently lower in AMD patients, and lutein/zeaxanthin supplementation slows progression in the intermediate stage (AREDS2 trial) risk increases with lower macular pigment.

Two strategies directly counteract reduced SR-BI efficiency. First, increasing dietary lutein and zeaxanthin density: the receptor can deliver more when more substrate is available. Kale, spinach, and egg yolks are the densest sources. Second, cooking and fat pairing: SR-BI requires that carotenoids be dissolved in fat micelles to access the receptor's uptake tunnel. Cooked (rather than raw) carotenoid-rich vegetables in the presence of fat increase bioaccessibility 3–6 fold.

Interactions

rs11057841 tags the carotenoid end of the SCARB1 functional haplotype, while nearby rs11057830 (r² ≈ 0.7) tags the vitamin E (alpha-tocopherol) end. Both represent reduced SR-BI function, so CC carriers at rs11057841 who are also GG at rs11057830 face compound reductions in both carotenoid and tocopherol absorption through this receptor — the two signals are partially independent, and the combined picture is more actionable than either alone.

A downstream interaction involves rs12934922 in BCO1 (beta-carotene 15,15'-oxygenase): rs11057841 CC determines how much dietary beta-carotene enters the body via SR-BI, while BCO1 rs12934922 determines how efficiently it is converted to retinol. Individuals who are CC at rs11057841 and carry the low-conversion BCO1 genotype absorb less beta-carotene AND convert less of it to vitamin A — a downstream compound effect that would warrant attention to preformed vitamin A sources.

Interleukin-1 beta (IL-1β) is one of the most potent pro-inflammatory cytokines in the body — it initiates fever, activates immune cells, induces other cytokines, and drives inflammation in virtually every tissue. The rs1143627 variant sits just 31 base pairs upstream of the IL1B transcription start site, in a region that directly controls how vigorously your immune cells turn on IL-1β production. The IL1B gene sits on the minus strand¹¹ The IL1B gene sits on the minus strand
On the plus strand, this variant is G→A; the coding-strand notation -31T>C reflects the minus-strand complement.

The Mechanism

The -31 position lies within the TATA-box region of the IL1B promoter²² TATA-box region of the IL1B promoter
The TATA box is a core promoter element recognized by transcription factor TFIID, which recruits RNA polymerase to begin transcription. The T allele (A on the genomic plus strand) creates a binding site configuration that permits higher basal and stimulated IL-1β transcription. When macrophages and dendritic cells encounter bacteria, viruses, or crystals (such as urate or cholesterol), the T-allele variants mount a more vigorous IL-1β response — producing more cytokine for the same immune stimulus.

This promoter variant is in near-complete linkage disequilibrium with the -511C>T variant (rs16944)³³ near-complete linkage disequilibrium with the -511C>T variant (rs16944)
The two promoter SNPs are almost always inherited together as a haplotype, so their effects are highly correlated in most populations. However, rs1143627 sits closer to the transcription start site and may independently influence transcription factor binding at the TATA box.

The Evidence

The clearest association is with gastric cancer in the context of H. pylori infection. A meta-analysis of 37 studies (6,108 cases, 8,980 controls) found the -31T allele increases gastric cancer risk specifically in H. pylori-positive individuals⁴⁴ meta-analysis of 37 studies (6,108 cases, 8,980 controls) found the -31T allele increases gastric cancer risk specifically in H. pylori-positive individuals
Homozygous model: OR = 1.35 (95% CI 1.02-1.78); heterozygous model: OR = 1.31 (1.04-1.66); recessive model: OR = 1.29 (1.04-1.61). The interaction is mechanistically plausible: H. pylori triggers massive NLRP3 inflammasome activation, releasing IL-1β; the -31T variant amplifies this IL-1β surge, creating a chronically inflamed gastric mucosa that accelerates progression from gastritis to metaplasia to carcinoma.

At the tissue level, H. pylori-positive dyspepsia patients with the TT genotype had 2.25-fold higher odds of moderate-to-severe chronic antral inflammation compared to CC+CT carriers (80.8% vs. 65.2%, OR = 2.25, 95% CI 1.23-4.24, p = 0.005)⁵⁵ H. pylori-positive dyspepsia patients with the TT genotype had 2.25-fold higher odds of moderate-to-severe chronic antral inflammation compared to CC+CT carriers (80.8% vs. 65.2%, OR = 2.25, 95% CI 1.23-4.24, p = 0.005), directly demonstrating how the variant amplifies inflammatory damage in infected stomachs.

Chronic periodontitis shows a parallel pattern. In an Indian case-control study (157 periodontitis patients, 200 controls), IL1B -31C/T was significantly associated with increased susceptibility to chronic periodontitis⁶⁶ In an Indian case-control study (157 periodontitis patients, 200 controls), IL1B -31C/T was significantly associated with increased susceptibility to chronic periodontitis
The variant was also part of the optimal gene-gene interaction model for disease risk alongside IL1B +3954 and IL-10 -819. Bacteria in subgingival plaque trigger the same NLRP3-IL-1β axis that H. pylori activates in the stomach; genetically amplified IL-1β production accelerates periodontal bone destruction.

In Kawasaki disease, children under 12 months with the AA genotype at rs1143627 had 2.28-fold increased risk of coronary artery lesions (OR = 2.28, 95% CI 1.32-3.95, p = 0.0032), with the adjusted OR reaching 2.33 in 719 KD patients and 1,401 healthy controls from southern China ⁷⁷ children under 12 months with the AA genotype at rs1143627 had 2.28-fold increased risk of coronary artery lesions (OR = 2.28, 95% CI 1.32-3.95, p = 0.0032), with the adjusted OR reaching 2.33 in 719 KD patients and 1,401 healthy controls from southern China . This implicates high IL-1β production in amplifying the vasculitis that damages coronary arteries in this disease.

In transplantation immunology, rs1143627 was significantly associated with acute graft-versus-host disease grade II-IV in pediatric HSCT recipients (p = 0.019)⁸⁸ rs1143627 was significantly associated with acute graft-versus-host disease grade II-IV in pediatric HSCT recipients (p = 0.019)
Carriers of risk alleles combined with HLA-B*15:01 had hazard ratio 2.14 (95% CI 1.41-3.25, p = 6×10⁻⁶), confirming the variant's role in driving severe alloimmune inflammation.

Practical Actions

For carriers of the A allele (T in coding notation), the most actionable implications are:

Gastrointestinal health: H. pylori testing is especially important. If H. pylori is detected, eradication should be prompt and confirmed — the combination of this variant and active infection creates the gene-environment interaction that most dramatically elevates gastric cancer risk. After eradication, periodic upper endoscopy surveillance is warranted if there is a family history of gastric cancer or if atrophic gastritis was found.

Periodontal vigilance: The genotype amplifies periodontal inflammation in the presence of dysbiotic gingival flora. More frequent professional cleaning (every 3-4 months rather than 6) and diligent home plaque control directly reduce the bacterial trigger for IL-1β release.

Systemic inflammation monitoring: Elevated IL-1β drives IL-6 production, which raises hsCRP. Tracking high-sensitivity CRP as part of routine health assessments captures the downstream inflammatory state this variant promotes.

Interactions

This variant is in near-complete linkage disequilibrium with rs16944 (-511C>T), the other well-studied IL1B promoter polymorphism. They are typically inherited together as the -511T/-31T haplotype (A/A on the plus strand), which compounds expression effects. The IL-1 gene cluster also includes IL1A (rs1800587) and IL1RN (interleukin-1 receptor antagonist); variants in IL1RN that reduce the IL-1 receptor antagonist can amplify net IL-1β biological activity even further⁹⁹ variants in IL1RN that reduce the IL-1 receptor antagonist can amplify net IL-1β biological activity even further
IL-1Ra normally dampens IL-1β signaling by competitive receptor binding.

Most people have never heard of ACAD9, yet it plays two essential roles inside every energy-demanding cell in the body. The protein encoded by ACAD9 — acyl-CoA dehydrogenase family member 9 — acts simultaneously as an enzyme that oxidizes long-chain fatty acids¹¹ enzyme that oxidizes long-chain fatty acids
Long-chain fatty acid oxidation (FAO) converts fat into acetyl-CoA for ATP production; ACAD9 specifically processes very-long-chain acyl-CoA substrates and as an indispensable assembly factor for mitochondrial complex I²² assembly factor for mitochondrial complex I
Complex I (NADH:ubiquinone oxidoreductase) is the first and largest enzyme of the mitochondrial electron transport chain; it transfers electrons from NADH to ubiquinone, pumping protons to drive ATP synthesis. Complex I deficiency is the most common cause of respiratory chain disease in humans. When the Ala326Pro variant disables ACAD9, both functions collapse, and the mitochondrial power supply to the heart, brain, and muscles is severely compromised.

The Mechanism

The c.976G>C substitution (rs115532916) replaces the flexible amino acid alanine at position 326 with the rigid cyclic amino acid proline. Proline is famously disruptive to alpha-helices and beta-sheets — it introduces a kink that few protein structures can accommodate. In ACAD9, this structural disruption abolishes ACAD enzyme activity³³ ACAD enzyme activity
Acyl-CoA dehydrogenase (ACAD) enzymes catalyze the alpha,beta-dehydrogenation of acyl-CoA esters; ACAD9 specifically targets long-chain (C12–C18) substrates, confirmed by functional studies cited in ClinVar and the Schiff et al. analysis of 16 ACAD9 variants.

The loss of ACAD9 protein function also depletes the complex I assembly scaffold. ACAD9 interacts with ECSIT and NDUFAF1⁴⁴ ECSIT and NDUFAF1
ECSIT (evolutionarily conserved signaling intermediate in Toll pathway) and NDUFAF1 (NADH:ubiquinone oxidoreductase complex assembly factor 1) form a trimeric complex with ACAD9 that nucleates the assembly of complex I's membrane arm, and in the absence of functional ACAD9, complex I cannot be fully assembled. The result is a profound biochemical energy deficit: cells cannot efficiently oxidize fats and cannot run the electron transport chain at capacity.

The Evidence

Haack et al. (2010, Nature Genetics)⁵⁵ Haack et al. (2010, Nature Genetics)
Haack TB et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet, 2010 established ACAD9 as a complex I deficiency gene using whole-exome sequencing. The original patient carrying Ala326Pro (in compound heterozygosity with a second ACAD9 variant, R532W) developed hypertrophic cardiomyopathy, encephalomyopathy, and lactic acidosis, with muscle complex I activity reduced to 26% of normal. That child died at age two. Restoring wild-type ACAD9 in patient-derived fibroblasts rescued complex I activity, confirming the causal role.

Schiff et al. (2015, Human Molecular Genetics)⁶⁶ Schiff et al. (2015, Human Molecular Genetics)
Schiff M et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet, 2015 analyzed 16 ACAD9 mutations across 24 patients and found a significant inverse correlation between residual ACAD enzyme activity and phenotypic severity. Both the enzymatic and scaffolding functions are clinically relevant — variants that eliminate only one function produce milder disease than those that eliminate both.

ClinVar lists this variant (VCV000030883) as Pathogenic/Likely pathogenic, with 8 of 9 submissions in agreement across nine independent diagnostic centers including GeneDx, Invitae, Great Ormond Street Hospital, and Baylor Genetics.

A therapeutically important subset of ACAD9 patients responds to high-dose riboflavin⁷⁷ riboflavin
Riboflavin (vitamin B2) is the precursor of FAD (flavin adenine dinucleotide), the essential cofactor bound by ACAD enzyme active sites. In riboflavin-responsive patients, supplemental B2 appears to stabilize residual ACAD9 protein and partially restore complex I assembly (vitamin B2). Gerards et al. (2011, Brain)⁸⁸ Gerards et al. (2011, Brain)
Gerards M et al. Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9. Brain, 2011 reported improved exercise tolerance and complex I activity in riboflavin-treated ACAD9 patients. However, Nouws et al. (2014)⁹⁹ Nouws et al. (2014)
Nouws J et al. A Patient with Complex I Deficiency Caused by a Novel ACAD9 Mutation Not Responding to Riboflavin Treatment. JIMD Rep, 2014 documented a fatal case where riboflavin supplementation had no effect, indicating that response is mutation-dependent. Variants that cause protein instability (rather than cofactor insufficiency) do not respond. The Ala326Pro variant causes loss of enzyme activity, so responsiveness must be assessed biochemically in each affected individual.

Practical Actions

Because ACAD9 deficiency is autosomal recessive, heterozygous carriers — one Ala326Pro allele plus one normal allele — have sufficient ACAD9 function and do not develop ACAD9 deficiency. The primary clinical significance of heterozygous carrier status is reproductive. If both parents carry a pathogenic ACAD9 variant, each pregnancy has a 25% chance of being affected.

Homozygous or compound heterozygous patients require urgent specialist management. A trial of high-dose riboflavin under metabolic specialist supervision is standard practice, with biochemical response assessed before and after supplementation. Additional interventions studied in riboflavin-non-responsive cases include bezafibrate and nicotinamide riboside, with limited but preliminary evidence of transient benefit.

Interactions

ACAD9 deficiency is caused by biallelic pathogenic variants — two mutations must be present to cause disease. The Ala326Pro variant is documented in compound heterozygosity with R532W in the original Haack et al. case. Any second pathogenic ACAD9 allele combined with Ala326Pro would be expected to produce ACAD9 deficiency. Genetic counseling should characterize both ACAD9 alleles in any suspected case.

Hidden in the machinery that controls cell division is an unexpected player in coronary artery disease. The ZC3HC1 gene¹¹ ZC3HC1 gene
encodes NIPA — Nuclear Interaction Partner of ALK — a protein that governs when cells transition into mitosis by controlling the nuclear accumulation of cyclin-B1, the key trigger of cell division. The rs11556924 variant swaps a single amino acid at position 363 — arginine to histidine — and this seemingly small change has genome-wide significant consequences for coronary artery disease risk.

This locus is unusual among cardiovascular GWAS hits. Most CAD-associated variants sit in regulatory regions of uncertain function, but rs11556924 is a direct coding change: the only nonsynonymous SNP in the landmark CARDIoGRAM consortium meta-analysis²² CARDIoGRAM consortium meta-analysis
22,233 CAD cases and 64,762 controls of European ancestry that identified 13 new susceptibility loci. The T allele (His363) carries an odds ratio of 0.90 for CAD — a 10% reduction in risk per allele — with a p-value of 2.4×10⁻¹⁷.

The Mechanism

NIPA acts as a molecular brake on mitotic entry. In dividing cells, cyclin-B1 must accumulate in the nucleus before cell division can proceed. NIPA controls the rate of this nuclear entry by responding to CDK1-mediated phosphorylation³³ CDK1-mediated phosphorylation
Cyclin-dependent kinase 1, the master regulator of mitosis. When CDK1 phosphorylates NIPA at Ser-395, it inactivates NIPA, allowing cyclin-B1 to accumulate and mitosis to proceed.

The R363H substitution alters this regulatory circuit. In cells carrying the risk C allele (Arg363), CDK1-mediated phosphorylation at Ser-395 is significantly slower (p=0.002), meaning NIPA remains active longer. Active NIPA holds cyclin-B1 out of the nucleus, reducing its stability there and slowing nuclear accumulation. The net result: risk-allele cells take approximately 3.4 additional minutes to complete mitosis compared to protective-allele cells (p=0.011).

The protective T allele (His363) shows a different phosphorylation profile. Functional validation using isogenic genome-edited cell lines⁴⁴ Functional validation using isogenic genome-edited cell lines
identical cells differing only at rs11556924 demonstrated that His363 NIPA has increased phosphorylation at Ser354, higher protein expression, and greater nuclear mobility — all consistent with faster inactivation and more permissive cell cycle control. Critically, His363 cells show reduced proliferation, which is the proposed mechanism of cardiovascular protection.

In vascular biology, the stakes are high. Vascular smooth muscle cells (VSMCs)⁵⁵ Vascular smooth muscle cells (VSMCs)
the primary cell type in the arterial wall undergo phenotypic switching from quiescent contractile cells to proliferative, migratory synthetic cells during atherogenesis. ZC3HC1 deficiency in VSMCs increases migration and promotes neointima formation — the hallmark of atherosclerotic plaque development — while also modulating cyclin-B1 levels and the SRF contractile gene program. Altered cell cycle control by the Arg363 variant may therefore sustain VSMC proliferation in the arterial wall, accelerating plaque growth.

The Evidence

The primary evidence comes from the CARDIoGRAM GWAS meta-analysis⁶⁶ CARDIoGRAM GWAS meta-analysis
Coronary ARtery DIsease Genome-wide Replication And Meta-analysis consortium, which combined 14 individual GWAS studies totaling 22,233 cases and 64,762 controls. Of the 13 newly identified loci, rs11556924 in ZC3HC1 was the sole coding variant, making it particularly tractable for functional follow-up. The OR of 0.90 per T allele is consistent across replication cohorts and represents a robustly replicated GWAS signal.

Beyond CAD, the C allele has been associated with hypertension in the Finnish TAMRISK cohort⁷⁷ hypertension in the Finnish TAMRISK cohort
769 participants at age 50, OR 1.42 for hypertension in CC carriers vs T allele carriers, 95% CI 1.10–1.84, suggesting effects on vascular function extend to blood pressure regulation. The T allele frequency varies markedly by ancestry: approximately 38% in Europeans, but only 5% in East Asians and 8% in Africans. This means about 43% of Europeans are homozygous CC, carrying the full two-dose risk.

The T allele frequency of 38% in Europeans means this is a common protective variant — the population-level effect is substantial. Each copy of the T allele reduces CAD risk by approximately 10%, and TT homozygotes (10% of Europeans) carry roughly 18% lower risk than CC homozygotes.

Practical Actions

The CAD-protective mechanism of the His363 variant operates through slower cell proliferation and altered VSMC phenotype. While carriers of the risk CC genotype cannot change their genotype, several interventions target the same cell cycle and vascular smooth muscle pathways implicated by this variant.

Monitoring cardiovascular risk factors — particularly blood pressure — is especially relevant for CC carriers. The TAMRISK data link CC to elevated hypertension risk, and blood pressure control is one of the most effective ways to reduce atherosclerotic progression independent of the genetic mechanism.

Omega-3 fatty acids (EPA and DHA) modulate VSMC phenotype and reduce proliferation through mechanisms that overlap with the ZC3HC1/cyclin-B1 pathway, including suppression of VSMC migration. Aspirin and antiplatelet therapy may also address the platelet-function dimensions of this variant's cardiovascular effects.

Interactions

ZC3HC1 operates within the broader cell cycle control network. The CDK1 pathway that phosphorylates NIPA is regulated by multiple upstream signals, and variants in cell cycle checkpoint genes could theoretically compound or mitigate ZC3HC1's effects. However, no published compound-action evidence currently exists for this specific interaction.

For cardiovascular risk, ZC3HC1 rs11556924 adds to polygenic scores alongside established CAD loci including rs4977574 (CDKN2A/B), rs9349379 (PHACTR1), and rs1333049 (9p21). These loci act through independent mechanisms — the 9p21 locus affects CDKN2A/B (cell cycle inhibitors), creating a potential directional interaction: individuals carrying risk alleles at both the 9p21 locus and ZC3HC1 face additive CAD risk through converging cell cycle dysregulation, though quantified compound-genotype risk estimates are not yet available in the published literature.

Most people think of gout as a disease of diet — too much red meat, beer, or shellfish. That is partly true. But your kidneys' ability to excrete uric acid is equally determined by genetics, and one of the less obvious players is ALPK1¹¹ ALPK1
Alpha-kinase 1, a serine/threonine kinase that serves as a cytosolic innate immune sensor for bacterial metabolites and also regulates urate transport in the kidney. ALPK1 encodes a kinase best known as the master switch of the ALPK1-TIFA-NF-κB signaling axis²² ALPK1-TIFA-NF-κB signaling axis
A cellular alarm system: ALPK1 detects bacterial metabolites (ADP-heptose), phosphorylates the adaptor protein TIFA, which then activates the pro-inflammatory transcription factor NF-κB, triggering cytokine production, the innate immune pathway that detects gram-negative bacterial metabolites and triggers inflammatory cytokine production. But ALPK1 also turns out to regulate URAT1³³ URAT1
The urate transporter 1, encoded by SLC22A12 — the primary transporter responsible for reabsorbing uric acid from urine back into the bloodstream in renal proximal tubules. Inhibiting URAT1 is the mechanism of the gout drug probenecid, the kidney protein responsible for reabsorbing urate from the urine back into the bloodstream. The Met861Thr variant (rs11726117, T>C on the plus strand) sits in the kinase domain of ALPK1 and disrupts this regulatory balance.

The Mechanism

ALPK1 normally acts as a negative regulator of URAT1 expression: higher ALPK1 activity suppresses URAT1, which reduces urate reabsorption and keeps serum uric acid lower. The C allele (Met861Thr) at rs11726117 is associated with altered ALPK1 function and, in kidney cells exposed to monosodium urate crystals⁴⁴ monosodium urate crystals
The needle-shaped crystals that form in joints and soft tissue when serum uric acid exceeds its solubility threshold (~6.8 mg/dL), triggering the acute inflammatory response of a gout attack, less effective suppression of URAT1 expression. The result is higher urate reabsorption, elevated serum uric acid, and increased susceptibility to both hyperuricemia and the inflammatory cascade that drives gout attacks.

The ALPK1 connection to inflammation matters beyond urate transport. ALPK1 phosphorylates TIFA⁵⁵ TIFA
TRAF6-interacting protein with a forkhead-associated domain — a molecular bridge between ALPK1 sensing and NF-κB activation, which in turn activates TRAF6 and NF-κB, triggering a cascade of pro-inflammatory cytokines. Monosodium urate crystals may tap into this same pathway, potentially amplifying joint inflammation in individuals whose ALPK1 variant produces a more reactive signaling state.

The Evidence

Ko et al.⁶⁶ Ko et al.
Ko AM et al. ALPK1 genetic regulation and risk in relation to gout. Int J Epidemiol, 2013 conducted a genome-wide association study of 1,351 Taiwanese aboriginal participants (511 gout cases, 840 controls) and found rs11726117 among the top hits, with the C allele carrying an odds ratio ≥1.44 (P ≤3.78×10⁻⁶). A replication in 511 Han Chinese participants confirmed the association, with OR ≥1.72 (P ≤4.08×10⁻³). The CC composite genotype with other ALPK1 variants showed OR = 1.83.

Kuo et al.⁷⁷ Kuo et al.
Kuo TM et al. URAT1 inhibition by ALPK1 is associated with uric acid homeostasis. Rheumatology (Oxford), 2017 provided functional evidence in 492 Han Chinese participants and a transgenic mouse model. ALPK1 overexpression significantly lowered URAT1 protein levels (P=0.0045), and the T allele at rs11726117 was associated with reduced gout risk via the SLC22A12 pathway (OR 0.39 — meaning T carriers have roughly 61% lower odds of gout versus C/C homozygotes in this model). Monosodium urate crystal exposure inhibited URAT1 expression through ALPK1 upregulation, suggesting a feedback loop that is disrupted by the Met861Thr variant.

Tu et al.⁸⁸ Tu et al.
Tu HP et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet, 2018 showed that combining ALPK1 CC with high-risk genotypes in ABCG2, SLC2A9, and SLC22A12 achieved a 99% positive predictive value for gout in Han Chinese (OR up to 55.0), underscoring the importance of ALPK1 in a polygenic gout risk model.

However, a Japanese replication study⁹⁹ Japanese replication study
Chiba T et al. Common variant of ALPK1 is not associated with gout: a replication study. Hum Cell, 2015 in 903 gout cases and 1,302 controls found no significant association (minor allele frequency 0.26 vs 0.25, p=0.44), suggesting the effect may be population-specific or modified by linkage disequilibrium differences between ethnic groups. This limits the evidence level to moderate.

Practical Actions

For individuals with the risk genotype (CC or CT), the most actionable implication is heightened attention to urate management. The ALPK1-URAT1 pathway points toward renal urate handling as the primary mechanism — meaning dietary strategies that reduce the urate load reaching the kidneys and pharmacological URAT1 inhibitors (when clinically indicated) are the most directly relevant interventions.

Monitoring serum uric acid is the first step: knowing your baseline uric acid level tells you whether ALPK1 genotype is translating into biochemical risk. Target below 6 mg/dL to prevent crystal formation, below 5 mg/dL if you have had prior gout attacks.

Interactions

The strongest interactions documented in the literature are with the major urate transporter genes: rs2231142 in ABCG2 (the intestinal urate exporter), rs505802 in SLC22A12/URAT1 (renal urate reabsorption), and rs3825016 in SLC22A12. Tu et al. (2018) showed that stacking ALPK1 CC with CC homozygosity at ABCG2 rs2231142 and risk alleles at SLC2A9 and SLC22A12 raised the predictive value for gout to near certainty. These compound effects reflect how urate metabolism is governed by a network of transporters — ALPK1 appears to be a regulatory node that amplifies or dampens the net effect of this transporter ensemble.

Your cells run on fat during fasting, prolonged exercise, and sleep. The first step of burning very long-chain fatty acids — chains of 14 to 20 carbons — depends on very long-chain acyl-CoA dehydrogenase (VLCAD)¹¹ very long-chain acyl-CoA dehydrogenase (VLCAD)
encoded by ACADVL on chromosome 17p13; the enzyme catalyzes the alpha,beta-dehydrogenation of fatty acyl-CoA esters in the inner mitochondrial membrane, the enzyme encoded by ACADVL. When both copies of this gene are severely disrupted, VLCAD deficiency (VLCADD) results — a rare inborn error of metabolism that can cause hypertrophic cardiomyopathy in infancy, hypoglycemia during fasting, or exercise-induced muscle breakdown in adults. The rs118204017 variant creates a phenylalanine-to-leucine substitution at residue 458, and has been classified as likely pathogenic²² classified as likely pathogenic
ClinVar VCV000001632; reviewed by the ClinGen ACADVL Variant Curation Expert Panel, 3-star review status, December 2022 by the ClinGen ACADVL Expert Panel. At a population frequency of roughly 1 in 40,000 chromosomes in gnomAD, it is exceptionally rare — meaning most people who carry one copy will never meet a partner who carries the same or another ACADVL variant.

The Mechanism

ACADVL encodes a homodimeric flavoenzyme³³ homodimeric flavoenzyme
VLCAD is a 70 kDa subunit homodimer anchored to the inner mitochondrial membrane; it works in concert with the mitochondrial trifunctional protein (MTP) to complete each cycle of fatty acid beta-oxidation that anchors to the inner mitochondrial membrane. Phenylalanine 458 sits within the acyl-CoA substrate binding channel of the mature enzyme. The substitution to leucine changes the shape of this channel, reducing catalytic efficiency for very long-chain substrates. Unlike null variants (frameshifts, nonsense, splice-site mutations) that abolish enzyme production entirely, missense variants like p.Phe458Leu typically preserve partial residual activity — estimated at roughly 20% of normal in one functional study — which is why homozygosity or compound heterozygosity for this variant tends to produce a milder clinical presentation than loss-of-function alleles. In a single heterozygous carrier, the one intact ACADVL copy produces sufficient enzyme for completely normal fatty acid oxidation.

The Evidence

The variant was first identified by Cox et al. in 1998⁴⁴ Cox et al. in 1998
Cox GF et al., J Pediatr 133:247–53 in an infant who presented at 5 months with severe hypertrophic cardiomyopathy, hepatomegaly, encephalopathy, and hypotonia — compound heterozygous for p.Phe458Leu on one allele and a splice site mutation on the other. The cardiomyopathy resolved substantially within one year on a low long-chain fat diet supplemented with medium-chain triglyceride (MCT) oil and carnitine, demonstrating that VLCADD-related cardiomyopathy is treatable when identified early.

The genotype-phenotype landscape was mapped by Andresen et al. 1999⁵⁵ Andresen et al. 1999
PMID 9973285, AJHG 64:479–494 across 55 unrelated patients with all clinical forms of VLCADD. Patients with severe early-onset disease consistently carried null variants on both alleles; those with the milder hepatic or adult myopathic forms carried at least one missense allele with residual enzyme activity. This genotype-severity correlation is significantly stronger in VLCADD than in the related MCAD deficiency, making variant classification clinically useful for anticipating prognosis. A large U.S. newborn screening cohort⁶⁶ large U.S. newborn screening cohort
Miller et al. 2015, PMID 26385305, Mol Genet Metab 116:139–45 of 693 VLCAD-screen-positive infants found that approximately 57% carried only a single ACADVL pathogenic variant, emphasizing that heterozygous carrier detection is an inherent feature of population-based newborn screening for this condition.

Practical Implications

Single-copy carriers of p.Phe458Leu are metabolically normal and require no dietary modifications or monitoring. The clinical relevance is entirely reproductive: if both partners in a couple carry a pathogenic ACADVL variant — whether this variant or any other — each pregnancy has a 25% chance of producing a child with VLCAD deficiency. Because VLCADD is an autosomal recessive disorder with an estimated birth prevalence of 1 in 30,000–100,000, the chance that a random partner is also an ACADVL carrier is roughly 1 in 100–200. Carrier couple identification before pregnancy allows access to prenatal testing, preimplantation genetic testing (PGT), or informed expectant management.

VLCADD identified early — through newborn screening or family cascade testing — is highly treatable. Management centers on reducing dependence on very long-chain fat oxidation: a diet low in long-chain triglycerides (LCT) with MCT supplementation, strict avoidance of fasting, and L-carnitine supplementation in some cases. Triheptanoin (C7 fat), an odd-chain anaplerotic MCT, received FDA approval in 2020 for the management of long-chain fatty acid oxidation disorders including VLCADD. Outcomes for newborn-screen-identified infants treated from birth are substantially better than for those diagnosed after symptom onset.

Interactions

rs118204017 is one of many pathogenic ACADVL variants; rs118204015⁷⁷ rs118204015 is a second ACADVL variant in this GeneOps batch. Compound heterozygosity for two ACADVL pathogenic variants — one on each chromosome — produces VLCAD deficiency in the same way as homozygosity; the severity depends on the residual enzyme activity of the two alleles combined. Compound heterozygosity for p.Phe458Leu and a null allele (the scenario in the original Cox 1998 case) produces a more severe phenotype than two missense alleles with partial residual activity. Carriers of rs118204017 who are also carriers of rs118204015 (or any other pathogenic ACADVL variant) on the opposite chromosome would be affected individuals, not unaffected carriers.

Vitamin C is not made by the human body. Every molecule of ascorbate¹¹ ascorbate
The active, ionized form of ascorbic acid at physiological pH in your bloodstream arrived via active transport: absorbed in the gut by SVCT1²² SVCT1
Sodium-dependent Vitamin C Transporter 1 — encoded by SLC23A1 on chromosome 5, expressed on the apical surface of intestinal enterocytes and proximal kidney tubule cells and then conserved by the kidneys, also by SVCT1, before filtered vitamin C can be lost in urine. rs11950646 sits in an intron of SLC23A1 — not in the protein-coding sequence, but in a region that influences how much transporter the gene produces. Carriers of the A allele have measurably lower plasma vitamin C on equivalent diets compared to those carrying the G reference allele.

The Mechanism

Unlike the SLC23A1 missense variant rs33972313 (Val264Met), which alters the SVCT1 protein itself, rs11950646 acts as a regulatory variant. Intronic sequences can harbour splice enhancer or silencer elements, secondary promoters, and binding sites for RNA-binding proteins. The mechanistic detail for this specific site has not been fully characterized in published functional studies, but the association with plasma vitamin C levels is reproducible. The most likely explanation is that the A allele reduces either the efficiency or quantity of functional SVCT1 protein produced from the transcript, subtly impairing both intestinal absorption of dietary vitamin C and renal reabsorption of filtered ascorbate.

The critical importance of SVCT1 for vitamin C homeostasis was established in a Slc23a1 knockout mouse model³³ Slc23a1 knockout mouse model
Corpe CP et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest, 2010: mice lacking the gene entirely excrete 18 times more ascorbate in urine than controls, nearly eliminating renal conservation capacity, and 45% of offspring die perinatally. rs11950646 represents a far milder perturbation, but its physiological direction is the same — more ascorbate lost, less retained.

The Evidence

The primary evidence comes from the EPIC cohort study by Duell et al. 2013⁴⁴ EPIC cohort study by Duell et al. 2013
Genes & Nutrition — 365 gastric cancer cases and 1,284 controls in the European Prospective Investigation into Cancer and Nutrition; four SLC23A1 and SLC23A2 SNPs independently predicted plasma vitamin C in multivariable regression models. In that study, rs11950646 was one of four genetic predictors of circulating ascorbate, alongside rs33972313 (SLC23A1) and two SLC23A2 variants (rs6053005, rs6133175). The effect operated independently of dietary intake — meaning even people with similar fruit and vegetable consumption showed genotype-driven differences in plasma vitamin C.

Broader context comes from a GWAS of 52,018 European individuals⁵⁵ GWAS of 52,018 European individuals
Zheng JS et al. Plasma Vitamin C and Type 2 Diabetes: GWAS and Mendelian Randomization in European Populations. Diabetes Care, 2021 that identified 11 genomic regions associated with plasma vitamin C (P < 5×10⁻⁸), with the strongest signal at SLC23A1 — confirming this transporter locus as the dominant genetic determinant of circulating ascorbate in European ancestry populations.

Mendelian randomization studies using SLC23A1 variants as genetic instruments have consistently found that genetically lower vitamin C does not causally drive disease outcomes such as cardiovascular disease, type 2 diabetes, or Alzheimer's disease — suggesting the observational associations between low vitamin C and disease risk are largely due to confounding (people with poor diets tend to have both lower vitamin C and higher disease risk). What the genetic data do confirm is that the SLC23A1 locus reliably and robustly predicts plasma ascorbate concentrations.

Practical Actions

The allele frequency pattern of rs11950646 is striking: the A allele (associated with lower vitamin C) is common in Europeans (~65%) and South Asians (~55%) but uncommon in Africans (~15%) and East Asians (~27%). This means the majority of people of European descent carry at least one copy of the A allele. For AA homozygotes (~36% of Europeans), both copies of the regulatory sequence carry the variant, and plasma ascorbate runs consistently lower relative to GG carriers on the same diet.

The practical consequence is similar to that of other SLC23A1 variants: your body is somewhat less efficient at capturing dietary vitamin C and retaining it through the kidneys. This does not require megadosing — intestinal absorption saturates at high single doses regardless of genotype. It means being consistently attentive to vitamin C intake, targeting food sources across the day (citrus fruits, bell peppers, kiwi, strawberries, broccoli), and potentially using a modest daily supplement (200–500 mg ascorbic acid) to ensure plasma levels stay comfortably above the adequacy threshold of ~28 µmol/L.

Interactions

rs11950646 acts on the same gene and same pathway as rs33972313 (the Val264Met missense variant). If both risk variants are present simultaneously — one altering the regulatory sequence and the other altering the transporter protein itself — the combined effect on vitamin C absorption and retention would be expected to be additive or compounding. Similarly, variants in SLC23A2 (which encodes SVCT2, the tissue-level vitamin C transporter responsible for delivery to the brain, adrenals, and immune cells) may interact with SLC23A1 variants to further reduce tissue-level ascorbate even when plasma levels appear borderline-adequate.

The thyroid stimulating hormone receptor (TSHR) is the defining autoantigen in Graves' disease — the most common autoimmune cause of hyperthyroidism. In Graves' disease, the immune system generates stimulating autoantibodies (TRAbs) that lock onto TSHR and permanently mimic the pituitary's TSH signal, driving uncontrolled thyroid hormone production. Understanding why these autoantibodies arise requires looking inside the thymus, where the immune system learns to distinguish self from non-self.

rs12101261 sits in intron 1 of TSHR within an [open chromatin regulatory region | A stretch of DNA accessible to transcription factors and regulatory proteins, indicating active gene regulation at this location] that controls TSHR expression in thymic epithelial cells. It is immediately adjacent to rs12101255, the more widely studied tag SNP for this locus — but the Stefan et al. PNAS 2014 mechanistic study¹¹ Stefan et al. PNAS 2014 mechanistic study
PMID 25122677 revealed that rs12101261 is the primary binding site for the transcriptional repressor PLZF, making it the functional heart of the Graves' susceptibility signal at this region.

The Mechanism

Within the intron 1 regulatory element, the transcriptional repressor [PLZF | Promyelocytic leukemia zinc finger protein; a transcription factor that recruits histone deacetylase complexes to silence gene expression] binds preferentially and more strongly to the disease-associated T allele at rs12101261. The C allele shows weaker PLZF affinity. When PLZF is bound — especially during interferon-alpha signalling triggered by viral infection, which enhances [H3K4me1 histone enrichment | A histone modification mark associated with active enhancer elements; its enrichment here during IFNα stimulation indicates epigenetic activation of the regulatory region] at this site — TSHR gene expression in thymic epithelial cells is suppressed.

The functional consequence is measurable in human thymus: Stefan et al.²² Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. PNAS 2014;111:12562–7 showed that TT homozygotes have a median thymic TSHR expression of 2.06 units versus 7.09 units in CT+CC carriers (P = 0.01) — a 3.4-fold reduction. Lower thymic TSHR means fewer TSHR-presenting thymic cells, which means autoreactive T cells that target TSHR escape the clonal deletion checkpoint and persist in the circulation. These escaped cells are the seed of the Graves' autoimmune response, awaiting an environmental trigger to activate them fully.

Viral infection is particularly potent as a trigger precisely because IFNα amplifies PLZF-mediated TSHR repression at this locus — creating a direct mechanistic link between common respiratory and enteric viral infections and Graves' disease onset in susceptible carriers.

The Evidence

rs12101261 was confirmed as an independent Graves' disease susceptibility variant in a large refined association study of 5,368 GD patients and 4,942 controls in the Chinese Han population³³ 5,368 GD patients and 4,942 controls in the Chinese Han population
Liu et al. European Journal of Endocrinology 2014; PMID 24144966. Using regression analysis of 74 genotyped and 922 imputed SNPs, rs12101261 and rs179243 emerged as the probable causal variants at the TSHR locus. Critically, GD patients carrying the susceptible rs12101261 genotype had significantly higher rates of persistent TRAb positivity after more than one year of treatment — meaning the variant predicts not just disease onset but also treatment resistance, a clinically actionable finding for patients choosing between antithyroid drugs, radioiodine, and thyroidectomy.

A 2019 haplotype study in 1,217 Chinese Han subjects (Sun et al. Int J Genomics 2019⁴⁴ Sun et al. Int J Genomics 2019
PMID 31565653) confirmed the C allele at rs12101261 as negatively correlated with GD. The protective GGCG haplotype (including C at rs12101261) showed OR = 0.56 (95% CI 0.46–0.67, P < 0.001) — the strongest haplotype-level protective signal at this locus.

The PLZF binding data from Stefan 2014 establishes the molecular basis for the association: this is not simply a tag SNP in linkage disequilibrium with a distant causal variant — the T allele itself is the biochemically active element that drives reduced thymic TSHR expression.

Practical Actions

TT homozygotes show ~3.4-fold reduced thymic TSHR expression compared with protective carriers, the largest effect size demonstrated at the molecular level for this locus. The clinical priority is early recognition of hyperthyroid symptoms and awareness of the viral trigger pathway. Establishing a baseline thyroid antibody panel before symptoms appear captures the pre-clinical window when TRAbs first appear.

Selenium at 100–200 mcg/day as selenomethionine has RCT-level evidence for reducing TRAb titres and autoimmune thyroid activity. Excess iodine is a documented Graves' disease precipitant and should be avoided in susceptible carriers. Given the finding that susceptible rs12101261 genotypes associate with persistent TRAb positivity after treatment, TT carriers who do develop Graves' disease may be stronger candidates for definitive treatment (radioiodine or thyroidectomy) over long-term antithyroid drug therapy — a conversation to have with an endocrinologist if GD is diagnosed.

Interactions

rs12101261 and rs12101255 share the same open chromatin regulatory element in TSHR intron 1 and are in strong linkage disequilibrium. rs12101261 appears to be the primary functional variant (the direct PLZF-binding site), while rs12101255 was historically studied first as the tag SNP. Together, they define the same Graves' susceptibility haplotype. rs179247, located ~18 kb upstream, is a third TSHR intron 1 variant in the same risk haplotype block.

Beyond the TSHR locus, Graves' disease has additional independent susceptibility loci: CTLA4 variants (rs3087243, rs231775) impair T-cell immune checkpoint function through an entirely separate mechanism; PTPN22 R620W (rs2476601) lowers T-cell activation thresholds. Carriers of multiple Graves' risk variants across these independent loci carry substantially higher cumulative susceptibility than any single locus predicts.

Every cell in your body requires zinc, but none more acutely than the enterocytes lining the duodenum and proximal jejunum. These cells express ZIP4, a protein encoded by SLC39A4 that acts as the primary gateway for dietary zinc absorption. When ZIP4 functions normally, it sits on the apical membrane of gut cells and actively imports zinc from food into the bloodstream. The Gly374Arg variant disrupts this gateway completely — the protein misfolds, never reaches the cell surface, and the body is left unable to absorb zinc through its normal intestinal route.

The Mechanism

The glycine at position 374 sits within the ZIP-family variable region of the transmembrane domain, a stretch conserved across zinc transporters because it is critical for correct protein folding. Replacing glycine — the smallest amino acid, with no side chain — with the bulky, positively-charged arginine introduces steric and electrostatic clashes that destabilize the transmembrane architecture. Functional studies in HEK293 cells¹¹ Functional studies in HEK293 cells
Wang et al., Acrodermatitis enteropathica mutations affect transport activity, localization and zinc-responsive trafficking of the mouse ZIP4 zinc transporter. Hum Mol Genet, 2004 showed that Gly374Arg retains immature glycosylation patterns, indicating the protein is trapped in the endoplasmic reticulum and never completes transit to the plasma membrane. The result is total loss of zinc uptake activity — not a partial reduction, but a complete block.

The Evidence

Acrodermatitis enteropathica (AE) is a rare autosomal recessive disease with a global incidence of approximately 1 in 500,000 newborns²² 1 in 500,000 newborns
StatPearls: Acrodermatitis Enteropathica, NCBI Bookshelf. The SLC39A4 gene was identified as the cause in 2002 when Küry et al. sequenced 8 affected families³³ Küry et al. sequenced 8 affected families
Küry S et al., Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet, 2002 and found the Gly374Arg substitution in homozygous form in one affected male. Subsequent mutation surveys have catalogued over 30 pathogenic SLC39A4 variants; Küry et al. 2003⁴⁴ Küry et al. 2003
Küry S et al., Mutation spectrum of human SLC39A4 in a panel of patients with acrodermatitis enteropathica. Hum Mutat, 2003 expanded the catalog to 21 mutations across 26 pedigrees, establishing that missense variants in transmembrane glycine positions are a recurrent disease mechanism.

The clinical phenotype is distinctive: affected homozygotes develop a triad of periorificial and acral dermatitis (sharply demarcated, crusted, psoriasiform plaques around the mouth, anus, and extremities), chronic diarrhea, and alopecia — typically within weeks of weaning from breast milk. Serum zinc falls below 70 µg/L. Secondary infections with Staphylococcus aureus and Candida are common. Without treatment, untreated AE is lethal within the first years of life.

Critically, the prognosis with treatment is excellent: zinc supplementation at 3 mg/kg/day of elemental zinc produces 100% symptomatic resolution, typically within one to three weeks, with complete normalization of skin, hair, and gastrointestinal findings. Schmitt et al. 2009⁵⁵ Schmitt et al. 2009
Schmitt S et al., An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Int J Dermatol, 2009 reviewed long-term outcomes and emphasized that supplementation must continue lifelong because the underlying transport defect is permanent.

Practical Actions

Carriers (one T allele) have one functional ZIP4 copy and absorb zinc normally under ordinary dietary conditions. No zinc supplementation is needed for carriers. However, knowledge of carrier status has family-screening implications: two carrier parents face a 1-in-4 risk with each pregnancy of having an affected child. Homozygotes require lifelong monitored zinc therapy; the key risks are zinc toxicity from over-supplementation and secondary copper depletion, as high zinc levels competitively inhibit intestinal copper absorption via metallothionein upregulation.

Interactions

The Gly374Arg variant causes full loss of ZIP4 function. Other pathogenic SLC39A4 variants (frameshift, splice-site, nonsense) also abolish transport; an individual who carries Gly374Arg on one allele and a different loss-of-function SLC39A4 variant on the other (compound heterozygous) is equally affected as a homozygote. Related population-common variation in SLC39A4 exists at rs1871534 (Leu372Val), which produces a mild reduction in zinc transport and shows extreme population stratification (near-fixation in West Africa); this common variant does not cause AE but may modestly affect zinc homeostasis in the context of dietary deficiency.

The IL12B gene¹¹ IL12B gene
located at 5q33.3, encodes the 40 kDa p40 subunit (also called IL-12B) shared by two structurally related but functionally distinct cytokines: IL-12 and IL-23. IL-12 pairs p40 with the p35 subunit to form the IL-12 heterodimer that drives Th1 differentiation and IFN-γ production. IL-23 pairs the same p40 subunit with the p19 subunit (IL-23A) to form IL-23, which drives Th17 cell expansion and IL-17 production. Both pathways converge on psoriatic skin inflammation — IL-12/Th1 produces the keratinocyte-activating IFN-γ while IL-23/Th17 produces the epidermal-hyperproliferation-driving IL-17. The rs12188300 variant lies near the IL12B gene in a 5q33.3 intergenic regulatory region and has been independently associated with psoriasis vulgaris in German, Polish, and Russian populations²² independently associated with psoriasis vulgaris in German, Polish, and Russian populations
Hüffmeier et al. identified the IL12B locus in a German GWAS; Malinowski et al. confirmed rs12188300 specifically in Polish patients.

The Mechanism

rs12188300 falls within the 5q33.3 regulatory region flanking IL12B, a genomic neighborhood containing multiple psoriasis susceptibility variants. The IL12B locus harbors a well-characterised risk haplotype defined by rs6887695 (upstream) and rs3212227 (3′ UTR)³³ risk haplotype defined by rs6887695 (upstream) and rs3212227 (3′ UTR)
rs12188300 is in moderate linkage disequilibrium with this haplotype and may itself tag regulatory elements controlling IL12B transcription. Functional studies of the IL12B risk haplotype demonstrate that risk-allele carriers show increased IL12B expression in monocytes, leading to elevated serum IL-12 and IFN-γ but paradoxically decreased IL-23 levels⁴⁴ increased IL12B expression in monocytes, leading to elevated serum IL-12 and IFN-γ but paradoxically decreased IL-23 levels
This skews the inflammatory milieu toward Th1 rather than Th17, yet both arms contribute to psoriatic disease. The net effect is a stronger pro-inflammatory IL-12/IFN-γ axis in carriers, amplifying the [positive feedback loop | IL-12 drives IFN-γ production, which in turn upregulates CXCL10 and further activates T cells, sustaining chronic skin inflammation] visible in psoriatic plaques.

The Evidence

rs12188300 was identified as part of the broader IL12B/5q33.3 psoriasis susceptibility locus in genome-wide studies. The TRAF3IP2 discovery GWAS Hüffmeier et al., Nature Genetics 2010⁵⁵ Hüffmeier et al., Nature Genetics 2010
Identified TRAF3IP2 as a new PsA and psoriasis susceptibility locus included 609 psoriatic arthritis cases and 990 controls in the initial scan, with replication across 6 European cohorts (5,488 individuals total), and also replicated the IL12B locus association. The most detailed replication comes from a Polish case-control study of 507 psoriasis patients and 396 controls⁶⁶ Polish case-control study of 507 psoriasis patients and 396 controls
Malinowski et al., Postepy Dermatol Alergol 2022, which found a minor allele frequency of 11.8% in psoriatic patients versus 8.7% in controls (p = 0.036), with a dominant-model odds ratio of 1.53 (95% CI 1.09–2.16, p = 0.014). The IL12B locus as a whole is among the most robustly replicated psoriasis susceptibility loci: a meta-analysis of 11 studies Zhu et al., 2013⁷⁷ Zhu et al., 2013
Meta-analysis of IL12B polymorphisms with psoriasis and psoriatic arthritis confirmed the IL12B risk haplotype's association with psoriasis (OR ~1.4) and psoriatic arthritis (OR ~1.5). The IL12B locus is additionally shared with Crohn's disease and ulcerative colitis risk, consistent with the [epidemiological overlap between psoriasis and IBD | Patients with psoriasis are approximately twice as likely to have Crohn's disease compared to the general population].

Practical Actions

For T allele carriers, the IL12B locus's relevance extends beyond disease risk to treatment response. Ustekinumab (Stelara) is a monoclonal antibody that binds directly to the p40 subunit encoded by IL12B, blocking both IL-12 and IL-23 signaling simultaneously. An Italian pharmacogenomic study⁸⁸ An Italian pharmacogenomic study
Galluzzo et al., Dermatology 2016 found that specific IL12B genotypes significantly predicted ustekinumab response in HLA-Cw6 positive patients. Carriers of the IL12B risk haplotype (elevated p40 expression) provide more target for ustekinumab blockade, but the relationship between rs12188300 specifically and treatment response has not been isolated from haplotype-level effects. Guselkumab and risankizumab target only the p19 (IL-23 specific) subunit rather than p40, so their efficacy is not directly influenced by IL12B expression levels in the same way. Carriers with psoriasis or psoriatic arthritis should discuss genotype-informed biologic selection with their dermatologist or rheumatologist, as the IL12B locus may help stratify responses.

Gut inflammation implications also deserve attention: the shared IL12B susceptibility between psoriasis and IBD means T allele carriers with digestive symptoms (persistent diarrhea, abdominal pain, blood in stool) warrant evaluation for subclinical inflammatory bowel disease, given the comorbidity rate is roughly double that of the general population.

Interactions

rs12188300 (IL12B) and rs33980500 (TRAF3IP2) were both identified in the same German GWAS screen for psoriasis susceptibility, pointing to partially overlapping but distinct pathways. TRAF3IP2 encodes Act1, an adaptor protein in the IL-17 receptor signaling cascade downstream of Th17 cells. Individuals carrying risk alleles at both IL12B (rs12188300, elevated IL-12 p40 production and Th1/IFN-γ amplification) and TRAF3IP2 (rs33980500, impaired Act1 function removing the IL-17-dependent negative feedback on Th17 cells) may have compounded susceptibility: the IL12B variant amplifies the IL-12/Th1 axis and increases p40 availability, while the TRAF3IP2 variant removes the downstream brake on Th17 expansion, allowing unchecked IL-22-driven keratinocyte proliferation. rs11209026 (IL23R R381Q) encodes a loss-of-function receptor variant that is strongly protective against psoriasis and IBD by dampening IL-23 signaling. Carrying both the IL12B rs12188300 T risk allele and the IL23R rs11209026 protective A allele represents a partially antagonistic combination, where increased p40 availability may be partially offset by reduced receptor sensitivity. The combined effect would benefit from compound action analysis once all three variants are genotyped.